Skip to main content
Loading
    • Oncology
    • Non-Profit/Patient Advocacy Group
    This is a three day course requiring attendance on all three days. "Advanced Business Development "(ABD) is a long-running course focusing on all key aspects of transactions in the biopharma industry. ...
  1. Translating Nobel Prize science into the clinic
  2. Copays Kill: How Cost Sharing Undermines Health
  3. Rescuing Promising but Shelved Assets: New Models to Overcome Barriers and Put Unmet Patient Needs First
  4. 35th Biotech Beyond Borders Report: Are Capital Markets Finally Coming Back?
  5. Next-Gen Advocates: Patients & Families Driving Breakthroughs in Rare Disease Drug Development
  6. AI in biologics drug discovery: analyzing the competitive landscape, technical approaches, and the industry's role.
  7. Novel Oncology Targets & Modalities Enter the Clinic - What’s Next?
  8. Fueling Innovation: Strategies for Funding Academic Spin Outs
  9. Foundation Models for Genomics: Current Advances and Future Directions
  10. Trusting the Machines: Designing Transparent AI Solutions for Healthcare
  11. Achieving Synergy: A Roadmap to Successful Academia-Industry Collaborations from Discussion to Implementation
  12. “Journey Into the [Un]validated” – a practical guide to partnering early with pharma on novel drug modalities!
  13. The Priority Review Voucher Program: Incentivizing Neglected Disease Research and Promoting Biotech Investment and Development for More than a Decade
  14. The New Era of Project Optimus: Implications for Oncology Development Strategy
  15. Advanced Business Development
  16. We’ve Entered a New Era of Neuropsychiatry: Precision in Practice
  17. Patient Diversity and Access to New Medicines – Can AI improve access in disadvantaged patient populations and optimize the economics of medical innovation?
  18. Flow of Capital to Women's Health : from innovation to patient
  19. What are the opportunities and challenges for the new generation of TechBio partnerships powered by Generative and Foundational AI?
  20. US Legal and Regulatory Framework, Challenges, and Opportunities for AI Use in Pharma Product Development
  21. From Discovery to Deals: Bridging the Valley-of-Death with a Molecule-to-Medicine Expressway
  22. The Innovation Race vs. Regulatory Pace: What to do when innovation outpaces regulation
  23. Oncology investment themes: where is the market putting its money?
  24. Undermining Innovation: How antimicrobial resistance imperils patients and threatens the future of medicine
  25. Best Practice for Genuine Sustainability- Pharmaceutical Companies in Latin America are Implementing Successful Sustainable Practices Without Resorting to Greenwashing.
  26. Shifting Attitudes Toward Vaccines Among Lawmakers
  27. Commercializing SBIR/STTR Technologies
  28. Expanding the reach of Cell Therapies: Shaping the Future of Autoimmune Disease Treatment
  29. Celebrating Women Leading Innovation in Biopharma
  30. Biotech M&A 2025: What’s Driving Deal Making in The New Environment
  31. Business Development Fundamentals
  32. Navigating regulations to bring cell/gene therapies to patients in Europe and Middle East
  33. Become a Biotech or MedTech Entrepreneur
  34. The Role of Small Investors in the Biotech Funding Landscape – a global perspective
  35. Guide to Raising Institutional Private Capital
  36. Trends in Dealmaking: Shaping Drug Development Through External Innovation
  37. Product & Company Valuation
  38. Commercialization Readiness From Preclinical to 1st Launch: The First Time CEOs Playbook
  39. Program Committee
  40. Master the Art of Business Development Negotiations
  41. Ethical and Practical Considerations for Multi-National Rare Disease Clinical Trials
  42. Optimizing Clinical Trial Design and Execution for Rare Diseases
  43. Policy Outlook: All Eyes on Intellectual Property Rights
  44. Building Winning Presentations and Using Emotional Intelligence as a Tool for Success
  45. Platform Licensing: Biotech and Pharma Perspectives
  46. Leveraging the Accelerated Approval Pathway for Rare Diseases
  47. Profit and Access: Groundbreaking Strategies to Make Medicines Available in Resource-Challenged Markets
  48. Companies should embrace RWE strategies early and often to enhance shareholder and stakeholder value throughout drug development and commercialization
  49. Fuel Your Innovative Cancer Breakthrough: From Unlocking Dilutive and Non-Dilutive Funding to Fostering Fruitful Partnerships
  50. Rapid response capabilities of global health and biosecurity countermeasures during outbreaks- leveraging public private partnerships.
  51. How to Best Scale CGT Manufacturing: Bringing Together Disparate Approaches
  52. It’s not “Just the Flu”: Harnessing innovation to save lives
  53. Platform Power: How Genetic Medicine Technologies Are Changing Expectations for Medicine
  54. The New Era of Mega Blockbusters: Advancing Drug Development for Broader Patient Impact
  55. Examining innovative business models for creating sustainable network and capabilities for public health and biosecurity countermeasures
  56. The “RNAissance” Era – Recent Breakthroughs, Future Prospects, and Challenges of RNA Therapeutics
  57. Co-Discovery and Co-Development Partnerships to Accelerate Next-Generation Medicines
  58. In Vivo CARs: Unlocking the Potential of Immune Cell Programming in Oncology and Beyond
  59. European biotech: Unlocking investment opportunities
  60. Weight Loss for Longevity? How metabolic drugs are disrupting chronic disease and improving healthspan
  61. INTELLECTUAL PROPERTY CONSIDERATIONS FOR INVENTIONS MADE BY, OR INVOLVING, ARTIFICIAL INTELLIGENCE
  62. Computational Drug Design: Benchmarking Bold Bets, Breakthroughs, and Bottlenecks
  63. “What If?” Preparing for Cybersecurity Risks Begins by Understanding AI’s Role in Attacks and Defense
  64. Scalable Biomanufacturing for Living Medicines: Pioneering the Future Today
  65. Understanding and Mitigating the Consequences of Loper Bright, Corner Post & Judicial Activities on Drug Development, Commercialization, and Investment
  66. AI in Biopharma: What’s Working and What’s left to prove
  67. Integrating AI-Driven Drug Discovery to Improve R&D Supply Chain Efficiency
  68. Accelerated Approval and Patient Need: The Value of Earlier Access
  69. Bridging the Innovation Valley of Death – a Call for Greater Pharma-Biotech-Academia Collaboration
  70. Healthcare AI Opportunities and Headwinds at NIH and the Ecosystem at Large: Fulfilling the Promise or Machine Learning Impaired?
  71. Preparing for the next generation in antimicrobial resistance: Combining traditional with non-traditional therapeutic approaches to tackle an ongoing pandemic
  72. We Still Need the People: AI/ML Drug Discovery is Here to Stay, but we Could be its Rate Limiting Factor
  73. In Pursuit of Health Equity: How Industry Has Evolved Its Focus On This Critical Healthcare Challenge
  74. Evolving from Patient Centricity to Integrated Patient Engagement- Change Management Experience and Key Learnings
  75. CI for the Biotech Journey: Applying Lessons from Pharma
  76. Advancing innovative risk-stratification tests that impact treatment pathway decisions: challenges in overcoming barriers to entry
  77. Beyond the Contract: Building Successful Biotech Partnerships
  78. Test Session
  79. Revolutionizing Drug Development: Harnessing New Approach Methodologies (NAMs) for a Safer Future in Medicine
  80. Beyond Innovation: Supercharging America's Biomanufacturing Infrastructure
  81. Building a Diverse Life Science Workforce for the Nation’s Bioeconomy: 4 industry-academic models
  82. Building and sustaining a comprehensive education and workforce development continuum to support an evolving industry: Massachusetts shares its lessons
  83. Bridging the biodata gap: Revolutionizing AI's impacts in biopharma by creating ‘digital twins’ of the natural world
  84. Weighing in on Weight Loss Medicine
  85. Innovative Patient-Focused Models for Accelerating Rare Drug Development
  86. An Eye on I&I: Innovations Fueling Growth
  87. Closing the practice gaps in precision oncology – what are the practical solutions?
  88. Global Puzzle: Decoding Cell Therapy Classifications in Europe and the USA
  89. Funding Workforce Diversity in Biomedical Innovation.
  90. Inflation Reduction Act (IRA) Litigation: Past and Future Impact on the Price Negotiation Framework
  91. Shaping Sustainability Strategies for Lasting Value
  92. Psychedelics Are Going Mainstream. Are you ready for it?
  93. Recognizing the “Why?” Behind Our Medicines: Patient Connection as a Motivator for Impact
  94. Expediting Impact: Leveraging the Patient Voice for Enhanced Clinical Trial Design and Accelerated Regulatory Approvals
  95. Overcoming Economic Challenges to Rare Disease Drug Development
  96. Attacking Cancer from All Angles: From ADCs to Immunotherapy
  97. Patient-reported Outcomes are Front and Center for Drug Development AND with the FDA and the CDC
  98. How VCs Evaluate Risk in Early Stage Startups
  99. Investors’ Perspectives – AI and Digital Health Investment Trends in 2025
  100. Carving out your ground in Immunology & Inflammation (I&I)
  101. Can AI in Drug Discovery Deliver More Than Just Faster, Cheaper Solutions?
  102. Effective Use of the New European Patent System as Part of your Global Patent Strategy
  103. From Skepticism to Opportunity: Building Investor Confidence in First-in-Class and First-in-Disease Drug Innovation
  104. Cracking the Code: Effective Biotech and Pharma Partnerships Unveiled
  105. Preparing for an IPO: Best Practices for Success
  106. Replacing Guesswork with Data: How Preclinical Human Models Are Driving More Predictive Drug Discovery
  107. Who Are Today’s Biotech Underdogs and What It Will Take for Them to Succeed
  108. Next-Gen Medicine: How Gene Editing and Epigenetics are Revolutionizing Health, Longevity, and Organ Transplantation
  109. Next-Generation Alzheimer's Disease Therapies
  110. Physician and patient perspectives on the impact of the Inflationary Reduction Act on drug development, access, and innovation
  111. An Investor and a Value Assessor Walk into a Bar
  112. Unlocking the Future: Opportunities and Challenges in Advanced Biologics Manufacturing
  113. Improving and Restoring Vision in Blinding Eye Diseases
  114. Partnering with the U.S. Government to Achieve Our National Security Mission
  115. The State of Emerging Biotechs: Investment, Deal, and Pipeline Trends
  116. Affiliate Event Test
Testimonials

Double Helix


 

Supporting Bank Sponsor


 

Premier Sponsors

Conference Sponsors